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Abstract
Attention-deficit/hyperactivity disorder (ADHD) is often comorbid with other psychiatric con-
ditions in adults. Yet, less is known about its relationship with common metabolic disorders
and how sex and ageing affect the overall comorbidity patterns of adult ADHD. We aimed to
examine associations of adult ADHD with several common psychiatric and metabolic condi-
tions. Through the linkage of multiple Swedish national registers, 5,551,807 adults aged 18
to 64 years and living in Sweden on December 31, 2013 were identified and assessed for
clinical diagnoses of adult ADHD, substance use disorder (SUD), depression, bipolar disor-
der, anxiety, type 2 diabetes mellitus (T2DM), and hypertension. Logistic regression models
and regression standardization method were employed to obtain estimates of prevalence,
prevalence difference (PD), and prevalence ratio (PR). All comorbid conditions of interest
were more prevalent in adults with ADHD (3.90% to 44.65%) than in those without (0.72%
to 4.89%), with the estimated PRs being over nine for psychiatric conditions (p < 0.001) and
around two for metabolic conditions (p < 0.001). Sex differences in the prevalence of comor-
bidities were observed among adults with ADHD. Effect modification by sex was detected
on the additive scale and/or multiplicative scale for the associations of adult ADHD with all
comorbidities. ADHD remained associated with all comorbidities in older adults aged 50 to
64 when all conditions were assessed from age 50 onwards. The comorbidity patterns of
adult ADHD underscore the severity and clinical complexity of the disorder. Clinicians
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should remain vigilant for a wide range of psychiatric and metabolic problems in ADHD
affected adults of all ages and both sexes.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a common childhood-onset neuropsychi-
atric disorder that often persists into later life [1]. The prevalence of ADHD has been estimated
to be 2.5–5% in adults [2, 3].
Clinical studies have documented that adults with ADHD tend to suffer from psychiatric
disorders such as substance use disorder (SUD), depression, bipolar disorder, and anxiety [4,
5]. Most of these studies, however, were based on small samples and non-standard assessment
approaches for either ADHD or the psychiatric conditions. Moreover, at least three important
questions remain to be addressed. First, it is unclear whether clinically diagnosed adult ADHD
is associated with common metabolic conditions, such as type 2 diabetes mellitus (T2DM) and
hypertension. Despite population-based evidence for an association between ADHD and
T2DM in children and adolescents [6], conclusions in adults remain uncertain [7]. With
regard to comorbid hypertension, the largest study to date reported an association between
three or more self-reported hyperactive-impulsive symptoms and hypertension in young
adults [8]. Clinical assessment of adult ADHD was, however, unavailable in the study. Second,
prior studies on sex differences in the comorbidity patterns of adult ADHD were mainly per-
formed in small clinical samples [9, 10], providing no evidence supporting sex differences in
the patterns. To ensure sufficient statistical power for such investigation, a large sample of
adults is needed. Third, although ADHD symptoms seem to persist even into senior age [11,
12] and remain associated with SUD, depression, and anxiety [13, 14], comorbidity rates in
elderly patients with ADHD have not been thoroughly investigated in a large representative
sample.
In this population-based cross-sectional study, we sought to provide a broader perspective
on the comorbidity patterns of adult ADHD by estimating associations of adult ADHD with
several common psychiatric and metabolic conditions, using data from the Swedish national
registers. Specifically, we aimed to replicate previously reported associations of adult ADHD
with psychiatric conditions, including SUD, depression, bipolar disorder, and anxiety, and
explore associations with metabolic conditions, in particular T2DM and hypertension. We
then assessed sex differences in these associations, and examined the comorbidity patterns of
adult ADHD in individuals aged 50 to 64 years.
Materials and methods
Data sources
All residents in Sweden are assigned a unique personal identity number that allows for large-
scale linkage across the Swedish national registers [15]. The Total Population Register was
established in 1968 and contains information on births, deaths, and migrations [16]. The
Swedish National Patient Register covers somatic inpatient care since 1968 and psychiatric
inpatient care since 1973, with complete national coverage achieved since 1987 (1973: 86%,
1986:98%) [17]. Since 2001 the register also covers approximately 80% of outpatient visits
including day surgery and psychiatric care from both private and public caregivers. Primary
care (e.g. general practitioners) is not yet covered in the register. The study was approved
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Study population
The study population consisted of 5,551,807 adults aged 18 to 64 years and living in Sweden
on December 31, 2013, who were identified from the Swedish Total Population Register. A
subgroup of 1,665,938 adults aged 50 to 64 were selected for exploring the comorbidity pat-
terns of adult ADHD in older adults.
Ascertainment of adult ADHD and comorbidities
Data on diagnoses of adult ADHD and comorbidities under study were retrieved from the
Swedish National Patient Register [17]. Ascertainment of adult ADHD was based on presence
of at least one diagnosis of ADHD (ICD-9: 314; ICD-10: F90) between age 18 and 64. Similarly,
ascertainment of each comorbid condition was based on presence of at least one diagnosis of
the condition between age 18 and 64. In the current study, we considered four psychiatric con-
ditions (SUD, depression, bipolar disorder, and anxiety) and two metabolic conditions
(T2DM and hypertension). ICD codes for all conditions can be found in S1 Table.
Statistical analysis
First, we estimated prevalence of each comorbid condition in adults with and without ADHD,
as well as the corresponding prevalence ratio (PR), using logistic regression models and regres-
sion standardization method [18]. The models were adjusted for two categorical covariates,
sex and age in years. For T2DM and hypertension, we conducted additional analyses restricted
to individuals without SUD, depression, bipolar disorder, and anxiety.
Second, we tested the presence of effect measure modification (hereinafter referred to as
effect modification) by sex on the observed associations. We began with estimating sex-strati-
fied PD for each comorbid condition, comparing adults with ADHD to those without. PD
thus reflects the absolute prevalence increase of a comorbid condition associated with ADHD.
To assess effect modification by sex on the additive PD scale for the associations, we calculated
difference in PD between females and males as
Difference in PD ¼ ðP11   P00Þ   ½ðP10   P00Þ þ ðP01   P00Þ ¼ ðP11   P10Þ   ðP01   P00Þ
Where Pij is the prevalence of a comorbid condition in the stratum of sex i and adult ADHD
status j, with i = 0 denoting male, i = 1 denoting female, j = 0 denoting absence of adult
ADHD, j = 1 denoting presence of adult ADHD. Essentially, difference in PD reflects whether
the joint effect of both female sex and adult ADHD on the prevalence difference scale is differ-
ent (difference in PD 6¼ 0) from the sum of the effects of female sex alone and adult ADHD
alone. Difference in PD = 0 indicates no effect modification by sex on the additive PD scale.
Next, we estimated sex-stratified PR for each comorbid condition, comparing adults with
ADHD to those without. To evaluate whether the associations were modified by sex on the
multiplicative PR scale, we calculated ratio of PR in females to PR in males for the comorbid
condition as
Ratio of PRs ¼ ðP11=P00Þ=½ðP10=P00Þ  ðP01=P00Þ ¼ ðP11=P10Þ=ðP01=P00Þ
Ratio of PRs reflects whether the joint effect of female sex and adult ADHD on the PR scale
is different (ratio of PRs 6¼ 1) from the product of the effects of female sex alone and adult
ADHD alone. Ratio of PRs = 1 indicates no effect modification by sex on the multiplicative PR
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scale. Despite assessment of effect modification by sex on two selected scales in the current
study, other scales might be of biological importance as well. For an association of interest,
effect modification by sex could be present on any scale but not necessarily all. Nevertheless,
assessing additive effect modification is considered important for identifying a target group for
intervention and thus more relevant to public health decision-making [19]. Logistic regression
models and regression standardization method [18] were used to obtain estimates of PD, dif-
ference in PD, PR, ratio of PRs, and 95% CI. The analyses were adjusted for age in years.
Finally, we explored the associations among older adults aged 50 to 64, with diagnoses of all
conditions being assessed from age 50 onwards. The analyses were adjusted for sex and age in
years.
Robust standard errors were calculated to construct 95% confidence intervals (CIs),
accounting for data clustering within the same families. The significance level for all tests was
set at p< .05, two-tailed. SAS software version 9.4 (SAS Institute Inc., Cary, NC) was used for
data mining. R software version 3.4.1 [20] was used for statistical analyses.
Results
The study population comprised 5,551,807 adults (49.19% females) aged 18 to 64 years (Mean
[SD] age: 40.55 [13.49] years) and living in Sweden on December 31, 2013, of whom 61,129
(1.10%) were diagnosed with ADHD at some point in their adult life. More descriptive infor-
mation on the distribution of sex, age, and number of psychiatric and metabolic conditions by
adult ADHD status is shown in Table 1.
Associations of adult ADHD with psychiatric and metabolic conditions
The prevalence estimates of SUD (35.12%), depression (42.28%), and anxiety (44.65%) were
more than nine times higher in adults with ADHD than in those without (Table 2). Bipolar
disorder, though relatively rare in the general adult population (0.72%), was highly prevalent
in adults with ADHD (14.29%), giving a PR of 19.96. Adults with ADHD showed an increased
prevalence of T2DM (3.90%) and hypertension (8.51%) compared to those without ADHD,
with PRs being 2.41 and 1.90, respectively (Table 2). All associations were still statistically sig-
nificant when the analyses were stratified by sex (Table 3). Furthermore, when the analyses
were restricted to individuals without SUD, depression, bipolar disorder, and anxiety, adult
ADHD remained significantly associated with T2MD (PR: 2.11, 95% CI: 1.79–2.42) and hyper-
tension (PR: 1.72, 95% CI: 1.56–1.89).
Sex differences in prevalence of comorbidities among adults with ADHD
Among adults with ADHD, depression, bipolar disorder, and anxiety were more prevalent in
females than in males, whereas SUD, T2DM, and hypertension were more prevalent in males
than in females (Fig 1). The most common comorbidity among females with adult ADHD was
anxiety, followed by depression, SUD, bipolar disorder, hypertension, and T2DM. The most
common comorbidity among males with adult ADHD was SUD, followed by anxiety, depres-
sion, bipolar disorder, hypertension, and T2DM (Fig 1).
Additive effect modification by sex
We observed additive modifying effects of sex on the associations of adult ADHD with all
comorbidities except T2DM (Table 3). For depression, bipolar disorder, and anxiety, adult
ADHD was associated with larger absolute prevalence increase (measured by PD) in females
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than in males (Table 3). For SUD and hypertension, adult ADHD was associated with larger
absolute prevalence increase males than in females (Table 3).
Multiplicative effect modification by sex
Multiplicative effect modification by sex was detected for the associations of adult ADHD with
all comorbidities except hypertension (Table 3). Females showed more elevated PRs for SUD,
bipolar disorder, and T2DM compared to males, while males had higher PRs for depression
and anxiety than females (Table 3).
Table 1. Descriptive characteristics of study population.
Characteristic With adult ADHD (N = 61,129) Without adult ADHD (N = 5,490,678)
N % N %
Sex
Female 26,737 43.74 2,704,211 49.25
Male 34,392 56.26 2,786,467 50.75
Age (years)
18–24 20,854 34.11 861,666 15.69
25–34 18,068 29.56 1,159,164 21.11
35–44 11,519 18.84 1,169,103 21.29
45–54 8007 13.10 1,207,419 21.99
55–64 2681 4.39 1,093,326 19.91
Number of psychiatric conditions other than ADHD
0 20,196 33.04 4,940,576 89.98
1 17,583 28.76 380,791 6.94
2 14,288 23.37 128,436 2.34
3 7466 12.21 36,258 0.66
4 1596 2.61 4617 0.08
Number of metabolic conditions
0 58,398 95.53 5,199,707 94.70
1 2,346 3.84 244,507 4.45
2 385 0.63 46,464 0.85
Affected by both psychiatric and metabolic conditions other than ADHD
No 58,828 96.24 5,430,337 98.90
Yes 2301 3.76 60,341 1.10
https://doi.org/10.1371/journal.pone.0204516.t001
Table 2. Associations between adult ADHD and comorbidities in adults aged 18 to 64a.
Comorbidity With adult ADHD (N = 61,129) Without adult ADHD (N = 5,490,678) PR 95% CI
N Prevalence, % 95% CI, % N Prevalence, % 95% CI, %
SUD 19,444 35.12 34.73–35.51 198,312 3.61 3.59–3.62 9.74 9.62–9.86
Depression 22,998 42.28 41.88–42.67 258,175 4.69 4.68–4.71 9.01 8.92–9.10
Bipolar Disorder 7123 14.29 13.98–14.60 39,403 0.72 0.71–0.72 19.96 19.48–20.43
Anxiety 25,376 44.65 44.25–45.05 269,015 4.89 4.88–4.91 9.12 9.04–9.21
T2DM 1044 3.90 3.68–4.13 89,565 1.62 1.61–1.63 2.41 2.27–2.55
Hypertension 2072 8.51 8.19–8.83 247,870 4.48 4.47–4.50 1.90 1.83–1.97
a Clinical diagnoses of adult ADHD and comorbid conditions were assessed between age 18 and 64. Estimates of prevalence and PR were adjusted for sex and age in
years.
SUD: substance use disorder; T2DM: Type 2 diabetes mellitus; PR: prevalence ratio; CI: confidence interval
https://doi.org/10.1371/journal.pone.0204516.t002
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Comorbidity of ADHD in older adults
When diagnoses of adult ADHD and comorbidities under study were assessed from age 50
onwards, the prevalence of ADHD was 0.29% in adults aged 50 to 64. The associations of adult
ADHD with all comorbidities remained statistically significant (Table 4).
Table 3. Modifying effects of sex on associations between ADHD and comorbidities in adults aged 18 to 64a.
Comorbidity PD, % 95% CI, % Additive effect modification by sex PR 95% CI Multiplicative effect modification by
sex
Difference in PDb, % 95% CI, % P value Ratio of PRsc 95% CI P value
SUD
Female 28.09 27.52–28.66 -6.96 -7.72 –-6.19 <0.001 11.06 10.84–11.28 1.23 1.20–1.26 <0.001
Male 35.05 34.52–35.57 8.97 8.84–9.10
Depression
Female 43.40 42.80–44.00 11.35 10.57–12.14 <0.001 8.39 8.28–8.50 0.84 0.82–0.85 <0.001
Male 32.05 31.53–32.56 10.03 9.87–10.18
Bipolar Disorder
Female 18.04 17.53–18.55 8.61 8.00–9.22 <0.001 20.78 20.16–21.40 1.10 1.04–1.15 <0.001
Male 9.43 9.07–9.78 18.94 18.21–19.67
Anxiety
Female 46.55 45.95–47.15 13.17 12.39–13.96 <0.001 8.52 8.42–8.63 0.84 0.82–0.85 <0.001
Male 33.38 32.86–33.90 10.17 10.02–10.32
T2DM
Female 2.30 1.97–2.63 -0.06 -0.52–0.40 0.792 2.79 2.53–3.05 1.27 1.12–1.42 0.001
Male 2.36 2.04–2.68 2.20 2.04–2.37
Hypertension
Female 3.40 2.95–3.86 -1.19 -1.83 –-0.55 <0.001 1.85 1.74–1.97 0.96 0.89–1.04 0.361
Male 4.59 4.14–5.04 1.92 1.83–2.01
a Clinical diagnoses of adult ADHD and comorbid conditions were diagnosed between age 18 and 64. All estimates were adjusted for age in years
b Difference in PD = PDfemale − PDmale
c Ratio of PRs = PRfemale/PRmale
SUD: substance use disorder; T2DM: Type 2 diabetes mellitus; PD: prevalence difference; PR: prevalence ratio; CI: confidence interval
https://doi.org/10.1371/journal.pone.0204516.t003
Fig 1. Age-adjusted prevalence estimates of psychiatric and metabolic conditions by sex and adult ADHD status in 5,551,807 individuals aged 18 to 64.
Adult ADHD and comorbid conditions were assessed between age 18 and 64.
https://doi.org/10.1371/journal.pone.0204516.g001
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Discussion
This large population-based investigation of common psychiatric and metabolic comorbidity
of adult ADHD generated three main findings. First, SUD, depression, bipolar disorder, anxi-
ety, T2DM, and hypertension were more prevalent in adults with clinically diagnosed ADHD
than in those without. Second, effect modification by sex was detected on the additive and/or
multiplicative scales for the associations of adult ADHD with all comorbidities. Finally,
ADHD remained associated with all comorbidities in adults aged 50 to 64, when all conditions
were assessed from age 50 onwards.
Our findings reinforce the associations of adult ADHD with SUD, depression, bipolar dis-
order, and anxiety found in prior studies [5, 21, 22]. The observed prevalence estimates of
SUD (35.12%), depression (42.28%), bipolar disorder (14.29%), and anxiety (44.65%) in adults
with ADHD were similar to previously reported [21, 23–25]. Although the mechanisms under-
lying these associations are not well understood, we know from both epidemiologic and
molecular genetic studies that a shared genetic predisposition might account for the co-exis-
tence of two or more psychiatric conditions [26–28]. In addition, individuals with ADHD may
experience increased difficulties as the demands of life increase, which may contribute to the
development of depression and anxiety [29].
Our findings about associations of clinically diagnosed ADHD with T2DM and hyperten-
sion might reflect health-risk behaviors among adult patients with comorbid ADHD. As others
have noted [30], inattention, disinhibition, and disorganization associated with ADHD could
make it difficult for patients to adhere to treatment regimens for metabolic disorders. ADHD-
associated deficits in delayed discounting [31] and reinforcement sensitivity [32] could impair
the future-oriented activities needed to promote physical health. It is also conceivable that
ADHD and metabolic disorders share underlying causes [7], such as oxidative stress [33],
immune dysfunction,[34] and inflammation [35]. The association between adult ADHD and
hypertension is especially intriguing, as one of the leading animal models of ADHD is the
spontaneously hypertensive rat [36] and two antihypertensive drugs, clonidine [37] and guan-
facine [38], are efficacious for treatment of ADHD. Yet, stimulant treatment for ADHD is
associated with increased systolic blood pressure [39], and it is unclear whether the association
between adult ADHD and hypertension observed in the current study was mediated by stimu-
lant treatment for ADHD. The topic deserves further investigation in a separate study. In addi-
tion, smoking and obesity are associated with ADHD [40, 41], while they also contribute to
insulin resistance [42, 43], a fundamental component of T2DM etiology, and hypertension
Table 4. Associations between adult ADHD and comorbidities in adults aged 50 to 64a.
Comorbidity With adult ADHD (N = 4,864) Without adult ADHD (N = 1,661,074) PR 95% CI
N Prevalence, % 95% CI, % N Prevalence, % 95% CI, %
SUD 1672 35.95 34.61–37.30 50,006 3.01 2.98–3.04 11.95 11.49–12.40
Depression 1757 38.79 37.43–40.16 53,593 3.23 3.20–3.25 12.03 11.59–12.46
Bipolar Disorder 712 15.43 14.39–16.46 10,802 0.65 0.64–0.66 23.72 22.06–25.38
Anxiety 1741 38.12 36.74–39.49 49,909 3.00 2.98–3.03 12.69 12.22–13.16
T2DM 253 6.10 5.38–6.82 58,958 3.55 3.52–3.58 1.72 1.52–1.92
Hypertension 674 16.65 15.54–17.76 170,191 10.24 10.19–10.29 1.63 1.52–1.73
a Clinical diagnoses of adult ADHD and comorbid conditions were assessed between age 50 and 64. Estimates of prevalence and PR were adjusted for sex and age in
years.
SUD: substance use disorder; T2DM: Type 2 diabetes mellitus; PR: prevalence ratio; CI: confidence interval
https://doi.org/10.1371/journal.pone.0204516.t004
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[44, 45]. This may serve as yet another explanation for the associations of ADHD with T2DM
and hypertension.
In contrast to our findings, the prevalence estimates of hypertension or other cardiovascular
diseases were similar between adults with ADHD and controls in a study based on U.S. health
care claims [46]. The discrepancy between their results and ours could to some degree be
attributed to differences in diagnostic criteria for ADHD; Diagnostic and Statistical Manual of
Mental Disorders (DSM) criteria used in the U.S. are not as strict as the ICD criteria used in
Sweden. Another potential explanation could be that patients with adult ADHD and their fam-
ily members are overrepresented in unemployment and thus less likely to be covered by
employer-sponsored health insurance [46], effectively introducing bias to the estimates in
their study.
Among adults with ADHD, we found that the prevalence estimates of depression, bipolar
disorder, and anxiety were higher in females than in males, whereas the prevalence estimates
of SUD, T2DM, and hypertension were higher in males than in females. The top three comor-
bidities of adult ADHD were all psychiatric conditions, namely, SUD, depression, and anxiety,
with the most common condition being anxiety in females and SUD in males. T2DM is the
least common comorbidity in both females and males with ADHD. Unlike prior studies show-
ing no evident sex differences in associations between adult ADHD and psychiatric comorbid-
ities [9, 10], we detected effect modification by sex on the additive scale and/or multiplicative
scale for the associations of adult ADHD with all psychiatric and metabolic comorbidities of
interest. When sex did not act as an effect modifier on one scale, it could still do on the other.
Without a more detailed pathophysiological understanding of an association, it is difficult to
speculate which scale is more biologically relevant. Hence, studies examining sex differences
exclusively on a multiplicative scale might overlook key information concerning sex-specific
mechanisms. There is general consensus among epidemiologists that assessing additive effect
modification is most appropriate for public health decision-making [19]. In the current study,
while females had higher baseline prevalence of depression, bipolar disorder, and anxiety than
males, adult ADHD was associated with larger absolute prevalence increase for these comor-
bidities in females than in males. Provided that these comorbidities could be prevented or mit-
igated through early detection and proper treatment of ADHD, targeting females with ADHD
could increase the efficiency of prevention for these conditions. Similarly, targeting males with
ADHD could increase the efficiency of prevention for SUD and hypertension. In addition,
more research is needed to explore whether the sex differences in absolute prevalence, PD, and
PR reflect sex-specific biological mechanisms underlying the associations.
Our findings about comorbidity of ADHD in older adults (50 to 64 years) provide a large-
scale corroboration of previous findings from a few available studies on this topic. One small
study of adults aged 60 to 94 years showed excess risk of depression and anxiety symptoms in
those with ADHD compared to those without [13]. Another small pilot study of adults aged 60
to 85 years reported elevated rates of SUD, mood disorders and anxiety disorders in individu-
als with ADHD compared to controls [14]. In the current study, despite a small proportion of
adults (0.29%) continuing to receive ADHD diagnosis at age 50 or older, associations with
ADHD were not limited to SUD, depression, and anxiety, but also bipolar disorder, T2DM,
and hypertension. Taken together, these findings highlight the need for more research in older
adults, even in those older than 65 years. Given that treatments for ADHD are effective in
improving ADHD symptoms, it is possible that such treatment may have a positive impact on
the psychiatric and metabolic outcomes in the aging population.
It should be acknowledged that the current study was subject to certain limitations. First,
ADHD was generally under-diagnosed in adults and largely overlooked in the older group
(aged 45 to 64 years by the end of 2013) primarily because ADHD as a diagnostic category was
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rarely considered for adults in Sweden before 2002. Patients treated in primary care or failing
to seek medical care were not covered by the National Patient Register. Consequently, the
study could not avoid a certain amount of false negatives, giving rise to an underestimation of
the associations. Second, all conditions under study were assessed via registered ICD diagno-
ses. Although differences in ICDs could lead to different estimates of point prevalence, patients
diagnosed with these conditions tended to represent relatively severe cases and have more fre-
quent visits to clinicians, which might induce detection bias and overestimation of the associa-
tions. Despite the first and second limitations, the true associations are still likely to be
statistically significant given the magnitude of the estimates. Third, although ADHD is a per-
sistent condition, its onset by diagnostic criteria typically precedes the onset of the comorbidi-
ties. Further, individuals who received the first diagnosis of ADHD in adulthood are likely to
be those who were undiagnosed and untreated in childhood. However, due to a lack of data on
outpatient specialty care before 2001 and primary care, we could not determine whether indi-
viduals with a diagnosis of ADHD in adulthood had ever been diagnosed in childhood, or
deduce the extent to which the development of comorbidities was related to delay in detection
and management of childhood ADHD symptoms. Neither could we infer the temporal order
of the onsets of the comorbidities. The intriguing question deserves thorough investigation in
future longitudinal research. Fourth, in the current study, 83.5% of all adults with an ADHD
diagnosis in the National Patient Register had at least one prescription of ADHD medication.
However, the Prescribed Drug Register was first introduced in July 2005, which makes it diffi-
cult to infer whether the initiation of pharmacological treatment for ADHD preceded the first
diagnoses of comorbid conditions. In addition, information on non-pharmacological treat-
ment is not available in the registers. Future research should therefore address the role of phar-
macological as well as non-pharmacological treatment for ADHD using appropriate study
designs.
In conclusion, the comorbidity patterns of adult ADHD underscore the severity and clinical
complexity of the disorder. Clinicians should remain vigilant for a wide range of psychiatric
and metabolic problems in ADHD affected adults of all ages and both sexes.
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